Venetoclax, a small-molecule B-cell lymphoma 2 (BCL-2) inhibitor, selectively eradicates
leukemic stem cells (LSCs). While venetoclax has revolutionized the treatment of acute …

Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …

Venetoclax is a B cell lymphoma 2 (BCL-2)–selective antagonist used to treat chronic
lymphocytic leukemia (CLL) and acute myelogenous leukemia (AML). Although this has …

Acute myeloid leukemia (AML) is a disease of the hematopoietic system that remains a
therapeutic challenge despite advances in our understanding of the underlying cancer …

Deregulation of cell death pathways such as apoptosis is a hallmark of cancer and
contributes to leukemogenesis and treatment failure in B-cell precursor acute lymphoblastic …

Venetoclax is a highly selective B-cell lymphoma-2 (BCL-2) inhibitor, which, combined with
a DNA hypomethylating agent or low dose cytarabine, results in high rates of initial …

Venetoclax is a specific B-cell lymphoma-2 (BCL-2) inhibitor that can restore activation of
apoptosis in malignancies, the survival of which depends on dysregulation of this pathway …

Deregulated apoptosis signaling is characteristic for many cancers and contributes to
leukemogenesis and treatment failure in B-cell precursor acute lymphoblastic leukemia …

Venetoclax, an oral BCL‐2 inhibitor, has been widely incorporated in the treatment of acute
myeloid leukaemia. The combination of hypomethylating agents and venetoclax is the …

BCL2 is an antiapoptotic protein commonly expressed in hematologic malignancies.
Overexpression of BCL-2 is a poor prognostic factor in acute myeloid leukemia (AML) …